Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
AssigneeThe Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
InventorsJacob George, Gad Keren
Life of this patent
Estimating the term…
Abstract
The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.
Claims18
A method of treating an inflammatory or autoimmune disease, comprising:
- administering to a patient in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising an anti eotaxin 2 monoclonal antibody comprising a heavy chain encoded by a nucleic acid having at least 90% homology with SEQ ID NO:1 and a light chain encoded by a nucleic acid having at least 90% homology with SEQ ID NO:2, or a fragment thereof which retains the binding activity of the antibody.
A method of treating an inflammatory or autoimmune disease, comprising:
- administering to a patient in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising an anti eotaxin 2 monoclonal antibody secreted by hybridoma D8 (ECACC Accession No. D809081702) or a fragment thereof which retains the binding activity of the antibody.
A method of treating an inflammatory or autoimmune disease, comprising:
- administering to a patient in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising an anti eotaxin 2 monoclonal antibody comprising a heavy chain encoded by a nucleic acid having at least 90% homology with the nucleic acid encoding the heavy chain of the monoclonal antibody secreted by hybridoma D8 (ECACC Accession No. D809081702) and a light chain encoded by a nucleic acid having at least 90% homology with the nucleic acid encoding the light chain of the monoclonal antibody secreted by hybridoma D8 (ECACC Accession No. D809081702), or a fragment thereof which retains the binding activity of the antibody.
Dependencies are inferred from the claim text.